Combining PI3K inhibitors with compounds that block other pathways and/or standard of care chemotherapy drugs is a logical approach for T-ALL treatment [40–42], but the rules that govern potential efficacy of combined pathway inhibition are unclear. This evidence concerns the gene PIK3CD and acute lymphoblastic leukemia.